Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks .

Recent Articles

Here’s the Bad News: All the Good News Already Is Priced into LK Stock

By Mark R. Hake, CFA Jan 22, 2020

Luckin coffee's growth is on a tear, but LK stock may be at a peak. LK stock already discounts huge growth rates in the future, including profits.

5 Dividend Stocks With Low Payout Ratios and High Yields

By Mark R. Hake, CFA Jan 21, 2020

These dividend stocks are the best of the best, offering low payout ratios and high yields. Keep an eye out for their prices to soar in 2020.

Nio Needs to Raise More Cash to Survive

By Mark R. Hake, CFA Jan 21, 2020

Nio stock is at a crossroads to raise the cash it needs to survive. Interest is due Feb. 1, but I think Nio will run out of cash by then.

Beyond the Growing Dividend, Abbvie Stock Is a Good Buy Here

By Mark R. Hake, CFA Jan 16, 2020

Abbvie stock is a cheap high-yield dividend stock the market overlooks. The Allergan deal, closing shortly, will boost earnings and dividends and push Abbvie stock higher.

Pfizer Stock Offers Good Value to Patient Investors

By Mark R. Hake, CFA Jan 15, 2020

Pfizer stock offers good value to patient investors. Pfizer's new spinoffs will provide a higher total return to the owners of Pfizer stock.